John Corbin

John Corbin is an accomplished biochemist with extensive experience in the biotechnology industry. Currently serving as the Chief Development Officer at BigHat Biosciences since May 2023, John previously held significant roles at Tizona Therapeutics, Inc. as Chief Technology Officer and SVP from November 2016 to June 2023, where responsibilities included overseeing CMC, Protein Sciences, and Antibody Discovery. At Gilead Sciences from August 2013 to November 2016, John was the Vice President of Antibody Development and a Senior Research Scientist, leading initiatives in therapeutic antibody engineering. John's earlier experience includes being an Associate Director at XOMA, where successful preclinical projects were developed, and a Postdoctoral Researcher at the University of Colorado, focusing on human protein signaling domains. John earned a Ph.D. in Biochemistry, Biophysics, and Signaling Biology from the University of California, Santa Cruz.